The Novel DNA Cross-Linking Agent KL-50 is Active Against Patient-Derived Models of New and Recurrent Post-Temozolomide Mismatch Repair-Deficient Glioblastoma

Medicine, Neurology, Oncology,
glioblastoma   DNA cross-linking agent   mismatch repair deficiency   temozolomide   KL-50   patient-derived xenograft models   novel therapy  

Breakthrough Study on KL-50 in Treating Recurrent Glioblastoma Background Glioblastoma (GBM) is a highly malignant brain tumor, particularly in patients with IDH wild-type (IDHwt), who have a very poor prognosis. Although the current standard treatment includes surgical resection, radiotherapy, and Temozolomide (TMZ) chemotherapy, most patients eve...

IDH Mutation, Glioma Immunogenicity, and Therapeutic Challenge of Primary Mismatch Repair Deficient IDH-Mutant Astrocytoma (PMMRDIA): A Systematic Review

Medicine, Neurosurgery, Oncology, Life Sciences, Immunology,
IDH mutation   glioma   immunogenicity   mismatch repair deficiency   astrocytoma   therapeutic challenge   systematic review  

Immunogenicity and Therapeutic Challenges of IDH-Mutant Gliomas Background Glioma is a common central nervous system tumor, and its treatment and prognosis vary significantly depending on molecular characteristics. In recent years, the diagnostic and prognostic significance of isocitrate dehydrogenase (IDH) mutations in gliomas has been increasingl...